Goldman Sachs analyst Matthew Sykes lowered the firm’s price target on Danaher (DHR) to $250 from $255 and keeps a Neutral rating on the shares after its Q4 revenue pre-announcement of flat % growth. The firm is also adjusting its organic growth assumptions for Danaher in FY25 to 6.0% from prior view of 6.6%, with majority of the delta coming out of Life Sciences where it now expects 4.5% organic growth vs. prior view of 5.9%, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher sees Q4 revenue up low-single digit percent range year-over-year
- Danaher announces investment partnership in Innovaccer
- Danaher price target lowered to $285 from $305 at Citi
- Danaher price target lowered to $268 from $278 at Evercore ISI
- Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls